Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125268361 | 12526836 | 1 | I | 20160629 | 0 | 20160701 | 20160701 | DIR | 57.00 | YR | M | N | 169.00000 | LBS | 20160630 | N | PH | COUNTRY NOT SPECIFIED |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125268361 | 12526836 | 1 | PS | CARBOPLATIN. | CARBOPLATIN | 1 | Intravenous bolus | Y | N | C051650AA | 20170430 | 0 | 500 | MG | Q3W | ||||
| 125268361 | 12526836 | 3 | C | BEVACIZUMAB | BEVACIZUMAB | 1 | 0 | ||||||||||||
| 125268361 | 12526836 | 5 | C | PENMETREXED | 2 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125268361 | 12526836 | 1 | Non-small cell lung cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125268361 | 12526836 | LT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125268361 | 12526836 | Chills | |
| 125268361 | 12526836 | Diaphragmatic disorder | |
| 125268361 | 12526836 | Dyspnoea | |
| 125268361 | 12526836 | Flushing |
Reporting Sources (this data is often not reported and may therefore be missing here)
| Event ID | CASEID | RPSR COD |
|---|---|---|
| 125268361 | 12526836 | HP |
Therapies reported
| no results found |